Organigram Global (OGI) Asset Writedowns and Impairment (2020 - 2026)
Organigram Global (OGI) posted quarterly Asset Writedowns and Impairment of $603053.1 for Q1 2026, down 53.61% on a QoQ basis from $1.3 million in Q2 2021.
Organigram Global (OGI) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Asset Writedowns and Impairment for 3 consecutive years, with $603053.1 the latest figure, recorded in Q1 2026.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $603053.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.4 million (changed N/A YoY) and the FY2025 annual result came in at $199098.0, down 93.57% from the prior year.
- Asset Writedowns and Impairment retreated to $603053.1 in Q1 2026 per OGI's latest filing, from $1.3 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for OGI reached as high as $603053.1 in Q1 2026 and fell as low as $603053.1 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Organigram Global | 89.89 Mn | 122.96 Mn | 28.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 603,053.11 |
| Mar 31, 2026 | 603,053.11 |
| May 31, 2021 | 1.30 Mn |
| May 31, 2021 | 1.30 Mn |
| Feb 28, 2021 | 500,000.00 |
| Feb 28, 2021 | 500,000.00 |
| May 31, 2020 | 27.99 Mn |
| May 31, 2020 | 27.99 Mn |